Innate Pharma   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Marseille France (1999)

Organization Overview

First Clinical Trial
2007
NCT01256073
First Marketed Drug
2018
moxetumomab pasudotox (Lumoxiti)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Innate FFAAP Medicines, L.L.C. | Innate Pharma | INNATE PHARMA | Innate Pharma, Inc. | Prothione, LLC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Arthritis (Phase 1)

Arthritis, Rheumatoid (Phase 1)

Carcinoma (Phase 3)

Carcinoma, Squamous Cell (Phase 3)

Esophageal Neoplasms (Phase 2)

Esophageal Squamous Cell Carcinoma (Phase 2)

Head and Neck Neoplasms (Phase 2)

Inflammation (Phase 1)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lymphoma (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Lymphoma, T-Cell, Peripheral (Phase 2)

Multiple Myeloma (Phase 2)

Mycoses (Phase 2)

Mycosis Fungoides (Phase 2)

Neoplasms (Phase 1)

Neoplasms, Plasma Cell (Phase 2)

Pneumonia (Phase 2)

Recurrence (Phase 1)

Sezary Syndrome (Phase 2)

Smoldering Multiple Myeloma (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 24
  • # of Trial APIs: 18